Rapid and strong de novo donor-specific antibody development in a lung transplant recipient

Short communication/case report

Andrew L. Lobashevsky, Kevin M. Rosner, John D. May, Michael D. Duncan, Chadi Hage, Erin N. Lushin, Eve E. Anderson, David W. Roe

Research output: Contribution to journalArticle

Abstract

A 66-yo female patient (typed B*39:01, 44:02) underwent first left single lung transplant (typed B*81:01, 15:17) on 02/07/2016 with negative for DSA in current and historical samples. On 02/17/2016 strong de novo DSA (MFI = 15,200, C1q +) to B81 were detected. The recipient has two children typed B*07:02, 44:02 B*27:03, 39:01, and had received multiple vaccinations. Twinrix, Zostavax and MMR vaccines contain viruses grown on live human lung fibroblasts (MRC-5, typed B*07:02, 44:02, and WI-38, typed B*08:01, 58:01). Each dose of vaccine used for injection is known to contain protein components of fibroblasts including HLA. Most likely rapid de novo DSA development is due to booster effect produced by five exposures to mismatched B locus alleles which share the following epitopes: 70IAQ, 65QIA, 65QIA + 76esn, 69aa + 80n, and 163ew + 73te. The later three consist of paired non-self and self eplets. Although likelihood of bystander effect produced by multiple vaccinations is low its impact cannot be ruled out.

Original languageEnglish (US)
Pages (from-to)17-21
Number of pages5
JournalTransplant Immunology
Volume40
DOIs
StatePublished - Feb 1 2017

Fingerprint

Vaccination
Herpes Zoster Vaccine
Fibroblasts
Communication
Tissue Donors
Measles-Mumps-Rubella Vaccine
Bystander Effect
Lung
Antibodies
Epitopes
Vaccines
Alleles
Viruses
Transplants
Injections
Proteins
Transplant Recipients
twinrix

Keywords

  • Antibodies
  • Epitope
  • HLA
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Transplantation

Cite this

Rapid and strong de novo donor-specific antibody development in a lung transplant recipient : Short communication/case report. / Lobashevsky, Andrew L.; Rosner, Kevin M.; May, John D.; Duncan, Michael D.; Hage, Chadi; Lushin, Erin N.; Anderson, Eve E.; Roe, David W.

In: Transplant Immunology, Vol. 40, 01.02.2017, p. 17-21.

Research output: Contribution to journalArticle

Lobashevsky, Andrew L. ; Rosner, Kevin M. ; May, John D. ; Duncan, Michael D. ; Hage, Chadi ; Lushin, Erin N. ; Anderson, Eve E. ; Roe, David W. / Rapid and strong de novo donor-specific antibody development in a lung transplant recipient : Short communication/case report. In: Transplant Immunology. 2017 ; Vol. 40. pp. 17-21.
@article{67489c66ed8f45af8d1a5fe791500fd3,
title = "Rapid and strong de novo donor-specific antibody development in a lung transplant recipient: Short communication/case report",
abstract = "A 66-yo female patient (typed B*39:01, 44:02) underwent first left single lung transplant (typed B*81:01, 15:17) on 02/07/2016 with negative for DSA in current and historical samples. On 02/17/2016 strong de novo DSA (MFI = 15,200, C1q +) to B81 were detected. The recipient has two children typed B*07:02, 44:02 B*27:03, 39:01, and had received multiple vaccinations. Twinrix, Zostavax and MMR vaccines contain viruses grown on live human lung fibroblasts (MRC-5, typed B*07:02, 44:02, and WI-38, typed B*08:01, 58:01). Each dose of vaccine used for injection is known to contain protein components of fibroblasts including HLA. Most likely rapid de novo DSA development is due to booster effect produced by five exposures to mismatched B locus alleles which share the following epitopes: 70IAQ, 65QIA, 65QIA + 76esn, 69aa + 80n, and 163ew + 73te. The later three consist of paired non-self and self eplets. Although likelihood of bystander effect produced by multiple vaccinations is low its impact cannot be ruled out.",
keywords = "Antibodies, Epitope, HLA, Vaccination",
author = "Lobashevsky, {Andrew L.} and Rosner, {Kevin M.} and May, {John D.} and Duncan, {Michael D.} and Chadi Hage and Lushin, {Erin N.} and Anderson, {Eve E.} and Roe, {David W.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.trim.2016.12.003",
language = "English (US)",
volume = "40",
pages = "17--21",
journal = "Transplant Immunology",
issn = "0966-3274",
publisher = "Elsevier",

}

TY - JOUR

T1 - Rapid and strong de novo donor-specific antibody development in a lung transplant recipient

T2 - Short communication/case report

AU - Lobashevsky, Andrew L.

AU - Rosner, Kevin M.

AU - May, John D.

AU - Duncan, Michael D.

AU - Hage, Chadi

AU - Lushin, Erin N.

AU - Anderson, Eve E.

AU - Roe, David W.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - A 66-yo female patient (typed B*39:01, 44:02) underwent first left single lung transplant (typed B*81:01, 15:17) on 02/07/2016 with negative for DSA in current and historical samples. On 02/17/2016 strong de novo DSA (MFI = 15,200, C1q +) to B81 were detected. The recipient has two children typed B*07:02, 44:02 B*27:03, 39:01, and had received multiple vaccinations. Twinrix, Zostavax and MMR vaccines contain viruses grown on live human lung fibroblasts (MRC-5, typed B*07:02, 44:02, and WI-38, typed B*08:01, 58:01). Each dose of vaccine used for injection is known to contain protein components of fibroblasts including HLA. Most likely rapid de novo DSA development is due to booster effect produced by five exposures to mismatched B locus alleles which share the following epitopes: 70IAQ, 65QIA, 65QIA + 76esn, 69aa + 80n, and 163ew + 73te. The later three consist of paired non-self and self eplets. Although likelihood of bystander effect produced by multiple vaccinations is low its impact cannot be ruled out.

AB - A 66-yo female patient (typed B*39:01, 44:02) underwent first left single lung transplant (typed B*81:01, 15:17) on 02/07/2016 with negative for DSA in current and historical samples. On 02/17/2016 strong de novo DSA (MFI = 15,200, C1q +) to B81 were detected. The recipient has two children typed B*07:02, 44:02 B*27:03, 39:01, and had received multiple vaccinations. Twinrix, Zostavax and MMR vaccines contain viruses grown on live human lung fibroblasts (MRC-5, typed B*07:02, 44:02, and WI-38, typed B*08:01, 58:01). Each dose of vaccine used for injection is known to contain protein components of fibroblasts including HLA. Most likely rapid de novo DSA development is due to booster effect produced by five exposures to mismatched B locus alleles which share the following epitopes: 70IAQ, 65QIA, 65QIA + 76esn, 69aa + 80n, and 163ew + 73te. The later three consist of paired non-self and self eplets. Although likelihood of bystander effect produced by multiple vaccinations is low its impact cannot be ruled out.

KW - Antibodies

KW - Epitope

KW - HLA

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85009453012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009453012&partnerID=8YFLogxK

U2 - 10.1016/j.trim.2016.12.003

DO - 10.1016/j.trim.2016.12.003

M3 - Article

VL - 40

SP - 17

EP - 21

JO - Transplant Immunology

JF - Transplant Immunology

SN - 0966-3274

ER -